VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

STATUS

Recruiting
End date

Apr 22, 2025
participants needed

60
sponsor

Henan Cancer Hospital

Send

Updated on 19 February 2024

See if I qualify

cyclophosphamide

prednisone

rituximab

lymphoma

bortezomib

epirubicin

marginal zone lymphoma

malt

Summary

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

Description

Marginal zone lymphoma (MZL) is a relatively common group of non-Hodgkin's lymphoma (NHL). The incidence rate is only inferior to diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Currently, NCCN guidelines recommend same treatment plan of FL like R-CHOP as the primary treatment for MZL. However, due to the great difference in cell origin and biological characteristics between FL and MZL, some patients can not achieve complete remission or relapse quickly after standard first-line treatment. A number of phase II clinical studies have evaluated the good efficacy of rituximab combined with chemotherapy in the treatment of MZL. Previous studies have shown that NF-B signaling pathway is in abnormal activation state in MZL. Velcade(Bortezomib), a proteasome inhibitor targeting NF-B pathway, has a promising therapeutic prospect in relapsed and refractory MZL. The goal of our trial is to assess the efficacy and safety of VR-CAP (Velcade and Rituximab-Cyclophosphamide, Epirubicin and Prednisone) in the first-line treatment for patients with marginal zone lymphoma.

Details

Condition	MALT Lymphoma, marginal zone lymphoma, marginal zone lymphoma
Age	18years - 70years
Treatment	Cyclophosphamide, Rituximab, Epirubicin, Prednisone, Velcade
Clinical Study Identifier	NCT04433156
Sponsor	Henan Cancer Hospital
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Age between 18 to 70 years old (including 18 and 70)
	Diagnosed as marginal zone lymphoma
	No receiving chemotherapy before enrollment
	Indications for treatment: 1) symptoms related to tumor; 2) end-organ function damage
	large mass; 4) continuous or rapid progress of disease; 5) patient's willingness
	Having at least one measurable lesions
	World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) 0-1
	Life expectancy no less than 3 months
	enough main organ function
	Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study
	Agreeing to sign the written informed consents
Exclusion Criteria
	Diagnosed as central nervous system lymphoma
	World health organization-Eastern Cooperative Oncology Group Performance tatus (ECOG) 2
	Other malignant tumor history or active malignant tumor need be treated
	Serious surgery and trauma less than two weeks
	Systemic therapy for serious acute/chronic infection
	Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months
	Active tuberculosis. Patients suspected of active TB need to be examined for chest X-ray, sputum and clinical symptoms and signs
	HIV-positive, AIDS patients and untreated active hepatitisHBV/HBV and HCV
	Patients with a history of deep vein thrombosis or pulmonary embolism less than 12 months
	Patients with a history of mental illness
	Researchers determine unsuited to participate in this trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

marginal zone lymphoma

malt

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma